Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
125678,"ELI LILLY AND COMPANY",IN,100000000088,1522.48,10/01/2014,"In-kind items and services",144086310,"","","A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED 24-WEEK STUDY FOLLOWED BY LONG TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS",https://clinicaltrials.gov/ct2/show/NCT02349295,"THE AMOUNT REPORTED REPRESENTS EITHER AN AGGREGATE OF CASH PAYMENTS -E.G. CLINICAL STUDY SERVICES, REIMBURSEMENTS FOR EXPENSES OR PASS-THROUGH COSTS- OR AN AGGREGATE OF IN-KIND VALUE -E.G. SUPPLIES, EQUIPMENT- PROVIDED BY LILLY OR BY A THIRD PARTY VENDOR IN CONNECTION WITH CLINICAL STUDIES DURING THE REPORTING PERIOD.  FOR AVAILABLE STUDY DETAILS, PLEASE VISIT CLINICALTRIALS.GOV."
125678,"Eli Lilly and Company",IN,100000000088,529.15,11/23/2015,"In-kind items and services",263816364,"","","A PHASE 3, MULTICENTER STUDY WITH A 36-WEEK OPEN-LABEL PERIOD FOLLOWED BY A RANDOMIZED DOUBLE-BLIND WITHDRAWAL PERIOD FROM WEEK 36 TO WEEK 104 TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF IXEKIZUMAB -LY2439821- 80 MG EVERY 2 WEEKS IN BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS",https://clinicaltrials.gov/ct2/show/NCT02584855,"The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
125678,"Janssen Research & Development, LLC",NJ,100000005592,30.00,01/20/2015,"In-kind items and services",263669958,SIRUKUMAB,"","Vaccine Response Substudy of: A Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy","",""
